The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- Response to Letters on my Mechanical Ventilation Article in the Ann Emerg Med - October 21, 2016
- Podcast 184 – Needle Cric (Again) and Transtracheal Jet Ventilation with Laura Duggan - October 16, 2016
- Podcast 183 – Driving Pressure with Dr. Roy Brower - October 3, 2016